title: CD20-negative pyothorax-associated B cell lymphoma.
abstract: We describe an 86-year-old male who developed CD20-negative pyothorax-associated B cell lymphoma 64 years after he had suffered from tuberculous pleuritis. Therapy with 8 courses of THP-COP at 2-week intervals was followed by involved-field radiotherapy of 30 Gy. Uncertain complete remission was achieved. Thereafter, local recurrence of pyothorax-associated lymphoma (PAL) at the primary site was seen. The patient received salvage radiotherapy of 50 Gy. The patient died of pneumonia during a second uncertain complete remission. The progression-free survival and overall survival of this patient were 10 and 15 months, respectively. When compared with the median survival of 9 months reported in the literature, the adverse effect of CD20 negativity on prognosis may not apply to PAL patients with an occasional aberrant phenotype.
authors.affiliation: Department of Internal Medicine, Takayama Red Cross Hospital, Takayama, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Fukuno
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanemura
authors.forename: Masaru
authors.initials: M
authors.lastname: Nishio
authors.forename: Shinobu
authors.initials: S
authors.lastname: Tanabashi
authors.forename: Kiyonao
authors.initials: K
authors.lastname: Okamoto
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004654:Empyema, Tuberculous / Q000150:complications*; D017809:Fatal Outcome; D006801:Humans; D016393:Lymphoma, B-Cell / Q000209:etiology* / Q000628:therapy; D008297:Male; D011014:Pneumonia / Q000209:etiology; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D018951:Antigens, CD20; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone